NervGen Pharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGEN.V research report →
Price Chart
About the company
NervGen Pharma Corp. , along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease.
- CEO
- Harold Martin Punnett
- IPO
- 2019
- Employees
- 11
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on NGEN.V
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $407.94M
- P/E
- -8.41
- Fwd P/E
- 4.42
- PEG
- 0.12
- P/S
- 0.00
- P/B
- 108.37
- EV/EBITDA
- -15.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17536.81%
- ROIC
- -719.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-25,079,252
- Net Income
- $-44,117,305-83.8%
- EPS
- $-0.60-66.7%
- OCF Growth
- -15.8%
- FCF Growth
- -15.8%
- 52W High
- $8.49
- 52W Low
- $2.57
- 50D MA
- $6.19
- 200D MA
- $4.60
- Beta
- 0.86
- RSI (14)
- 41
- Avg Volume
- 90.11K
No earnings-call transcripts are available for NGEN.V yet.
- Free Float
- 83.8%
- Shares Outstanding
- 79.21M
- Float Shares
- 66.35M
Our NGEN.V coverage
Recent articles, reports, and earnings notes.
No research on NGEN.V yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGEN.V report →